157 related articles for article (PubMed ID: 36266779)
1. Trend of circulating CD34
Iurlo A; Galli N; Bucelli C; Artuso S; Consonni D; Cattaneo D
Br J Haematol; 2023 Feb; 200(3):315-322. PubMed ID: 36266779
[TBL] [Abstract][Full Text] [Related]
2. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Predictive Factors for Early Response to Ruxolitinib in 320 Patients with Myelofibrosis From the Polish Adult Leukemia Group (PALG) Registry.
Góra-Tybor J; Gołos A; Mikulski D; Helbig G; Sacha T; Lewandowski K; Niesiobędzka-Krężel J; Bieniaszewska M; Wysogląd H; Grzybowska-Izydorczyk O; Seferyńska I; Sobas M; Czyżewska M; Michalska A; Sawicki W; Mazur M; Hus M; Bodzenta E; Olszewska-Szopa M; Włodarczyk M; Patkowska E; Świstek W; Jamroziak K
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e19-e26. PubMed ID: 36396583
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.
Chen YY; Huang CE; Lee KD; Chen CC
Hematology; 2016 Jan; 21(1):3-9. PubMed ID: 26214121
[TBL] [Abstract][Full Text] [Related]
6. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
[TBL] [Abstract][Full Text] [Related]
7. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.
Mesa RA; Verstovsek S; Gupta V; Mascarenhas JO; Atallah E; Burn T; Sun W; Sandor V; Gotlib J
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):214-221.e1. PubMed ID: 25682576
[TBL] [Abstract][Full Text] [Related]
8. Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.
Breccia M; Andriani A; Montanaro M; Abruzzese E; Buccisano F; Cedrone M; Centra A; Villivà N; Celesti F; Trawinska MM; Massaro F; Di Veroli A; Anaclerico B; Colafigli G; Molica M; Spadea A; Petriccione L; Cimino G; Latagliata R
Ann Hematol; 2017 Mar; 96(3):387-391. PubMed ID: 27889820
[TBL] [Abstract][Full Text] [Related]
9. Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.
Miller CB; Komrokji RS; Mesa RA; Sun W; Montgomery M; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):479-487. PubMed ID: 28606598
[TBL] [Abstract][Full Text] [Related]
10. Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome.
Palandri F; Tiribelli M; Breccia M; Bartoletti D; Elli EM; Benevolo G; Martino B; Cavazzini F; Tieghi A; Iurlo A; Abruzzese E; Pugliese N; Binotto G; Caocci G; Auteri G; Cattaneo D; Trawinska MM; Stella R; Scaffidi L; Polverelli N; Micucci G; Masselli E; Crugnola M; Bosi C; Heidel FH; Latagliata R; Pane F; Cuneo A; Krampera M; Semenzato G; Lemoli RM; Cavo M; Vianelli N; Bonifacio M; Palumbo GA
Cancer; 2021 Aug; 127(15):2657-2665. PubMed ID: 33794557
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Ruxolitinib versus Best Available Therapy in Treating Primary Myelofibrosis.
Hasan KM; Elmeshhadany AY; Shabila NP
Sultan Qaboos Univ Med J; 2022 Aug; 22(3):393-399. PubMed ID: 36072080
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence.
Harrison CN; Talpaz M; Mead AJ
Leuk Lymphoma; 2016 Oct; 57(10):2259-67. PubMed ID: 27463690
[TBL] [Abstract][Full Text] [Related]
13. Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study.
Gupta V; Griesshammer M; Martino B; Foltz L; Tavares R; Al-Ali HK; Giraldo P; Guglielmelli P; Lomaia E; Bouard C; Paley C; Tiwari R; Zor E; Raanani P
Leuk Lymphoma; 2021 Apr; 62(4):918-926. PubMed ID: 33210570
[TBL] [Abstract][Full Text] [Related]
14. Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.
Devos T; Selleslag D; Granacher N; Havelange V; Benghiat FS
Hematology; 2022 Dec; 27(1):23-31. PubMed ID: 34957926
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis.
Breccia M; Luciano L; Pugliese N; Rossi E; Tiribelli M; Scalzulli E; Bonifacio M; Martino B; Latagliata R; Benevolo G; Caocci G; Binotto G; Martinelli V; Cavo M; Pane F; De Stefano V; Foà R; Palandri F
Ann Hematol; 2019 Aug; 98(8):1933-1936. PubMed ID: 31201513
[TBL] [Abstract][Full Text] [Related]
16. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.
Palandri F; Breccia M; Bonifacio M; Polverelli N; Elli EM; Benevolo G; Tiribelli M; Abruzzese E; Iurlo A; Heidel FH; Bergamaschi M; Tieghi A; Crugnola M; Cavazzini F; Binotto G; Isidori A; Sgherza N; Bosi C; Martino B; Latagliata R; Auteri G; Scaffidi L; Griguolo D; Trawinska M; Cattaneo D; Catani L; Krampera M; Lemoli RM; Cuneo A; Semenzato G; Foà R; Di Raimondo F; Bartoletti D; Cavo M; Palumbo GA; Vianelli N
Cancer; 2020 Mar; 126(6):1243-1252. PubMed ID: 31860137
[TBL] [Abstract][Full Text] [Related]
17. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 - 100 × 10
Talpaz M; Prchal J; Afrin L; Arcasoy M; Hamburg S; Clark J; Kornacki D; Colucci P; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):336-346. PubMed ID: 34911667
[TBL] [Abstract][Full Text] [Related]
19. Trends in overall mortality among US veterans with primary myelofibrosis.
Tashi T; Yu J; Pandya S; Dieyi C; Scherber R; Parasuraman S
BMC Cancer; 2023 Jan; 23(1):48. PubMed ID: 36641455
[TBL] [Abstract][Full Text] [Related]
20. Management of myelofibrosis after ruxolitinib failure.
Harrison CN; Schaap N; Mesa RA
Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]